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Abstract
Therapy decisions in advanced medullary thyroid carcinoma should be guided by a critical appraisal of the natural
disease course (slowly progressive vs. aggressive) and benefits and side effects of therapy. Therapy goals should be
distinguished between curative and palliative. Local treatments are mainly palliative and may add to quality of life.
The advent of novel systemic therapies opens promising perspectives but its place in the therapeutic arsenal must
be further determined.
Introduction
Distant metastases in medullary thyroid carcinoma
(MTC) are frequently present at initial presentation in
sporadic MTC patients [1,2]. Organs most often affected
include the lungs, bones and liver, and infrequently the
brain. Distant metastases are frequently associated with
persistent locoregional disease [3]. Patients with distant
metastases at diagnosis have a poor prognosis, with only
40% surviving 10 years [2].
Treatment goals
Treatment goals in advanced MTC are ultimately
related to promoting the quality of life. It is important
to explicitly discuss with the patient the expectations
and goals with respect to quality of life in the individual
context and to agree on a personalized treatment plan.
In general, it is important to document the sites of
metastases and the tumor volume as well as tumor pro-
gression to get an estimate of total tumor burden and
prognosis. In addition, it is necessary to document signs
and symptoms and estimate imminent problems. In
patients with recurrent disease, an acceptable quality of
life can usually be maintained for months or even years.
Treatment decisions must therefore balance the usually
slow progression rate and the reasonable life expectancy
against the efficacy and side effects of therapies.
An important step is to decide whether any therapy
will be curative or palliative, as the risk-benefit ratio of
curative therapies is essentially different from palliative
therapies. Curative therapies will by definition be aimed
at improved survival and disease-free survival. The main
objective of palliative therapies is to improve quality of
life by relief of symptoms. When recurrent local disease
is present or distant metastases are limited to a single
organ curative surgical resection may be considered.
Unfortunately, in advanced MTC, curative options are
limited as both local recurrent disease and metastases
are seldomly amenable to curative surgery. Active treat-
ment is most often indicated in patients with lesions in
critical locations such as brain metastases, threatening
spinal cord compression, airway obstruction, bleeding,
impending or active fracture or hormonal secretion.
Documenting disease and disease progression
The discovery of metastases is often preceded by detectable
or increasing serum levels of calcitonin or CEA. It must
however be stressed that elevated levels of tumor markers
are not a reason in itself to start therapies. Elevated tumor
markers, and especially a low doubling time of serum
calcitonin and CEA are rather considered risk factors for
the presence and development of metastases and a poor
prognosis [4,5]. Indeed, disease progression should always
be confirmed by imaging before considering treatment.
Patients who have elevated stable tumor markers without
demonstrable tumor may have a good prognosis and
quality of life [6-8]. Those patients are being followed with
serum tumor marker measurements and regular imaging,
the interval depending on the serum marker level and
doubling time [1,4,5].
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Imaging should identify all clinically relevant sites of
disease, both for the identification of tumors that
require local interventions and the selection of potential
target lesions to assess response to systemic therapy.
Imaging procedures in metastatic MTC include conven-
tional contrast-enhanced spiral CT scan or MRI of the
brain, neck, chest and liver and bone scintigraphy [3].
Diagnostic accuracy of Fluorodeoxyglucose (FDG)- PET
scan is questionable [3,9]. F-DOPA-PET scintigraphy is
promising and may provide additional information on
tumor localization in patients with elevated tumor mar-
kers without evidence of disease on conventional ima-
ging. However, the impact on clinical decision making
needs to be confirmed [10].
In patients with measurable lesions, it should be eval-
uated if curative therapy is possible. When no curative
options are present, disease progression must be docu-
mented. Usually, criteria for the initiation of systemic
treatment are defined according to RECIST in combina-
tion with considerable tumor burden and/or symptoms.
Local disease
Recurrent disease in the neck and mediastinum is fre-
quently amenable to surgery, with either curative or pal-
liative intent. Repeat surgery may normalize calcitonin
levels in one third of patients and progression free survi-
val may be fairly good, although no controlled studies
have been performed. Surgical resection of locoregional
recurrent MTC in patients without distant metastases
should include compartmental dissection of disease in
the neck compartments. In the presence of incurable
advanced local or distant disease, less extensive neck sur-
gery may be appropriate to avoid complications [11-13].
The role of external beam radiation therapy (EBRT) in
recurrent local MTC is not clear. In patients with local
disease in whom no curative surgery is possible, EBRT
may improve locoregional disease control, although an
improvement in overall survival has not been established
[14].
Distant metastases
Distant metastases limited to a single organ may be con-
sidered for curative surgical resection or another local
treatment modality. Slow growing or stable metastases
without clinical symptoms may be followed, the interval
of imaging depending on the size of the tumor and the
progression rate.
Local treatment modalities for distant metastases
Brain metastases
Clinically overt brain metastases from MTC are reported
in 1–5% of MTC patients with local or metastatic disease
[3]. Brain metastases are suspected in MTC patients with
neurologic symptoms especially when distant metastases
are present. Brain imaging should be performed in
asymptomatic MTC patients before initiation of systemic
therapy [15-17]. When small brain lesions are discovered,
it may be decided to follow-up without treatment. In
clinical studies in differentiated thyroid carcinoma and
other tumors, it has been suggested that surgical resec-
tion in patients with solitary or a limited number of brain
metastases may be associated with improved survival and
quality of life [15-17]. Other treatment options include
stereotactic radiosurgery or whole brain EBRT for clini-
cally overt brain metastases.
Bone metastases
Bone metastases occur in 45% of MTC patients with
local or metastatic disease [3]. Small, asymptomatic
bone metastases can be followed without treatment. Iso-
lated bone metastases may be surgically resected. In
some studies in differentiated thyroid carcinoma, it has
been suggested that surgery is worthwhile when 5 or
less bone metastases are present [18]. It is not known if
these results can be expanded to MTC. EBRT in symp-
tomatic bone lesions may lead to considerable reduction
in pain in 80% of patients, which may last for months
[14]. Experience from other tumors learns that sympto-
matic bone metastases can be successfully treated with
percutaneous methods including cementoplasty, thermal
ablation (radiofrequency or cryotherapy) and arterial
embolization followed by surgery, or a combination of
these methods, for pain reduction and bone consolida-
tion [19,20]. Intravenous bisphosphonates are prescribed
frequently for painful bony metastases in other malig-
nancies, but this has not been investigated in MTC [21].
Lung metastases
Lung metastases occur in 33% of MTC patients with local
or metastatic disease [6]. In solitary lesions, surgical resec-
tion, either by open procedure or video assisted thoraco-
scopy can be considered. Alternatively, asymptomatic,
stable or slowly progressive lesions can be followed. Lung
or mediastinal lesions causing local compression of an air-
way or bleeding may be considered for surgery or EBRT,
and lesions with central airway invasion may be amenable
to the photodynamic therapy or airway stenting (when the
tumor is >15 mm from the vocal cord) to improve quality
of life [22]. Radiofrequency ablation may be indicated in
patients with few ( <5,) predominantly peripheral lung
metastases of < 40 mm in size.
Liver metastases
Liver metastases occur in 45% of MTC patients with local
or metastatic disease [6] . In large, progressive liver
metastases or metastases associated with symptoms, local
treatment is required. Treatment options include resec-
tion or percutaneous radiofrequency ablation. RFA may
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lead to prolonged symptom reduction in 90–95% of
patients, including reduction of diarrhoea. Radiofre-
quency ablation is less effective in lesions > 50 mm
[23,24].
Systemic treatment
Conventional chemotherapy in patients with advanced
MTC has limited efficacy, and considerable toxicity and
is therefore not recommended [1].
In recent years, several kinase inhibitors have been
evaluated in phase I and II clinical trials, including axiti-
nib, cabozantinib (XL-184), lenvatinib (E7080), motesa-
nib, pazopanib, sorafenib, sunitinib and vandetanib
[25,26]. In phase II trials, several of these agents have
demonstrated partial response rates in the range of 20–
50% with a larger number of patients demonstrating pro-
longed stable disease. Two of these agents, vandetanib
and cabozantinib have completed phase III clinical trials.
Vandetanib (300 mg/day) [27] prolonged median pro-
gression free survival from 19 months in the placebo arm
to a predicted median of 31 months in the vandetanib
arm; the improvement of pain and diarrhoea allowed a
number of patients in the vandetanib arm to resume a
normal social life. However, 12% of patients receiving
vandetanib discontinued treatment due to toxicity and
35% required dose reduction because of an adverse event.
Vandetanib was approved by the FDA in April 2011 and
by the EMEA in February 2012. Cabozantinib (175
mg/day) prolonged PFS prolongation from 4 to 11 months
and was approved by the FDA in November 2012 [28].
However, short-term toxicity of these therapies is signifi-
cant, with dose reduction or treatment withdrawal in a sig-
nificant proportion of patients; longterm toxicity needs to
be investigated. There is currently no evidence for a higher
treatment efficacy at an earlier than later stage when the
tumor has progressed. This should lead to initiating these
treatments only in patients with significant tumor burden
and documented tumor progression.
Other therapies
Therapies with immunization [29] and radiolabelled
molecules have been performed in MTC sometimes
with promising results. Treatment with 131-I-MIBG is
generally regarded as ineffective for MTC [30].
Treatment of hormonally active metastases
MTC is an endocrine active tumor and secretion of hor-
mones other than calcitonin is frequently observed.
Diarrhoea [31] is frequently present when tumor volume
is high. Diarrhoea can be treated with anti-motility
drugs including somatostatin analogues. When these
therapies are not sufficient, local therapies to reduce
tumor volume can be considered. Sometimes, CRH or
ACTH production leads to Cushing syndrome, which
may be a reason for local tumor reduction, cortisol
synthesis inhibitors or bilateral adrenalectomy [32].
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